A revolutionary Ai tries can help slash the risk of dying prostate cancer till half, a discovery study suggests.
From the classroom images you could identify patients who could benefit of a game drug “of the game to pick up the features in the human eye.
Around one in four men with “Departed Lifting” cancer has been found a particular biomarker that made you more receptive to treatment.
Between those who biomarker, taking the drug to the drug the time of the death therapy after five years from 17 percent – a reduction of 47 per cent.
Men without the Biomarkker has seen his or her drop risk of the 7 per cent 4 percent – which is not intended to be statistically or clinically significant.
Abignone, that costs right to £ 77 for the supply of a month from the principle will be behaved, it works in the test production throughout the body, including in the text.
Ai revolutionary test can help dying risk by prostate cancer until half, a discovery study suggests (illustration of protruding)
The researchers say Nhs England should do the drug available to 2.100 men to the year that might benefit, while spreading the other a treatment that comes with additional side effects.
It is approved in the duty duties with the attached cancell’s patients and is partitioning in other parts of the body but not for the year in year that is not spilled.
The experts say fewer men who first thought the drug, NHS England should review decision for those who could benefit before.
It was more widely available for men in Scotland and Wales for two years.
Sciencials from the Cancer Directions (ICR), in London, and University London London Examination by more than 1. Men that were tumbers were risky.
The scores, based on a test developed by Artera inc, will be presented in the American meeting of meeting clinical on Chicago.
The mail has lived for years to improve the diagnosis and prostate cancer treatment in an offer to prevent useless dead.
Today Nick James, who led the search in ICR, I am looking for me to the pursuit of the drug that has shared. ‘
The scientists of research Cancer and University London (portrait) data from more than 1,000 men whose tumors were in high risk of spreading
A NHHS portrait: ‘Abiraterone continuously financed by England for many advanced prostate forms, and we don’t have place under a tight review.’
Meanwhile cancer cancer patients
The “liquid biopsy” waits small fragments of tumor the DNN and detect the mutation.
About 15,000 patients a year, benefit, the NHS England says.
